Charles River Laboratories International, Inc. (NYSE:CRL) will look for merger and acquisitions (M&A). President and Chief Executive Officer James Foster said, "we're looking to find, assess and validate new capabilities and technologies, which we then either sign up for partnerships, invest organically or acquire through M&A. As you can see with our move into cell and gene therapy, we're staying abreast of emerging therapies and new modalities. And we are definitely investing in areas with the greatest potential for growth.

We're focusing on synergies from M&A and acquisitions, process optimization, harmonization in our legacy business and the scalability of our operating model".